EE Impact

Gilead Sciences

USA · Pharma & Healthcare

LeaveRussia detail: Pausing Investments

Operations suspended

Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Status last verified 03/08/2026Source checked 18/02/2023Company website ↗LeaveRussia profile ↗

Decision trail

Decision date 24/03/2022 · Reference ↗

Received revenues in Russia in 2021. While remain committed to facilitating patient access to life-saving medicines in Russia, all non-essential business operations in the country have been suspended. Any profits made from the sale of medicines will be donated to the humanitarian efforts for Ukraine. The initiation of new clinical trial sites in Russia and Ukraine has been paused.

Local stats (LeaveRussia)

Assets(RF), mln.USD
16
Capital(RF), mln.USD
4
Revenue(RF), mln.USD
14
Staff(RF), 2021
56
Taxes(RF), mln.USD
1

Status history since 2022

  1. 03/08/2026 suspended · Imported from KSE LeaveRussia

Exposure profile

Full exposure profile is a Professional feature

Energy, transport and commodity exposure, supplier/customer links in the region and sanctioned-party proximity.

Upgrade to Professional
Statuses, logos and narrative notes are compiled from public reporting and the KSE LeaveRussia project. Found an error? See our corrections policy.